Kyverna Therapeutics is trading 8.8% down at $6.20 in pre-market, with no fresh company-specific announcement identified to explain the decline.
- Recent coverage highlighted positive one-year miv-cel trial data released September 24.
- Kyverna targets completing the rolling BLA submission in fourth-quarter 2026; neither item establishes a cause for the decline.
- Provided broader market indicators are positive, so they do not explain the move as a same-direction market decline.